Sipavibart vs. Tixagevimab/Cilgavimab for COVID-19 Prevention in Immunocompromised Patients
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on April 4th, 2025
|
Although COVID-19 vaccines have been highly effective, many immunocompromised individuals are unable to benefit from their protection. To address this, antibody combinations such as tixagevimab and cilgavimab—targeting the viral spike protein—have been utilized. However, the emergence of resistant variants has created a need for novel treatments. Funded by AstraZeneca, a study was conducted to evaluate the use of sipavibart in preventing COVID-19 infection.
The phase 3 clinical trial, conducted from March to October 2023, enrolled 3,349 immunocompromised participants who were unable to receive the COVID-19 vaccine. Participants were randomly assigned to receive either 300 mg of sipavibart or the current regimen of 300 mg of tixagevimab combined with 300 mg of cilgavimab. Both treatments were administered as intramuscular injections in two doses, spaced 6 months apart. The researchers found that sipavibart reduced the risk of SARS-CoV-2 infection by 34.9% more than the tixagevimab-cilgavimab combination. This superior effectiveness was consistently observed against the XBB and BA.2.86 variants, although it was not statistically significant for the JN.1 variant or variants carrying the Phenylalanine-to-Leucine mutation at position 456 on the spike protein.
The phase 3 clinical trial, conducted from March to October 2023, enrolled 3,349 immunocompromised participants who were unable to receive the COVID-19 vaccine. Participants were randomly assigned to receive either 300 mg of sipavibart or the current regimen of 300 mg of tixagevimab combined with 300 mg of cilgavimab. Both treatments were administered as intramuscular injections in two doses, spaced 6 months apart. The researchers found that sipavibart reduced the risk of SARS-CoV-2 infection by 34.9% more than the tixagevimab-cilgavimab combination. This superior effectiveness was consistently observed against the XBB and BA.2.86 variants, although it was not statistically significant for the JN.1 variant or variants carrying the Phenylalanine-to-Leucine mutation at position 456 on the spike protein.